[ad_1]
On New Year’s Eve, China approves the first coronavirus vaccine, which was undoubtedly the key element of 2020.
According to Reuters, no full data on the vaccine’s effectiveness has been released so far, but the developer at the Beijing Institute of Biological Products, affiliated with Sinopharm China National Biotec Group (CNBG), said on Wednesday that the vaccine has a 79.34% success rate. prevention of the development of COVID-19 disease (intermediate data).
The approval, announced by the National Medical Products Administration, comes after the United Arab Emirates became the first country to launch the vaccine this month. Pakistan has also signed a purchase agreement for 1.2 million doses of the Sinopharm vaccine.
Although it is the first country in the world to face the virus, China has moved slower than other states in approving a COVID-19 vaccine. However, the Chinese did not sit still, instead testing 3 different types of vaccines (two developed by CNBG and one by Sinovac Biotech) for months.
The Asian country launched an emergency program in July for key employees and others at high risk of infection, administering more than 15 million doses of vaccine.
In fact, China brings at least five vaccines developed by Sinovac, CNBG, CanSino Biologics and the Chinese Academy of Sciences to fight the coronavirus. These are in the last stages of studies.
President Xi Jinping is committed to making China’s vaccines a global public good and has won several major supply deals with countries such as Indonesia and Brazil (the most populous countries in Southeast Asia and Latin America, respectively).
China’s announcement comes a day after the Oxford-AstraZeneca vaccine against COVID-19 was approved in the UK.
To know the most important news of the day, transmitted in real time and presented in an equidistant way, like our Facebook page!
Follow Mediafax on Instagram to see amazing images and stories from around the world!
The content of the website www.mediafax.ro is intended exclusively for your information and personal use. Is prohibited republish the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, contact us at [email protected].
[ad_2]
